gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Breast cancer 1, early onset

Iris, BRCA1
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009] (from NCBI)
Top mentioned proteins: CAN, HAD, AGE, p53, iMpact
Papers using Iris antibodies
The cell cycle hypothesis of Alzheimer's disease: Suggestions for drug development
Smith Mark A. et al., In International Journal of Medical Sciences, 2006
... monoclonals recognizing BRCA1 amino acids 1-304 (Clone MS110, Oncogene Research Products), rabbit polyclonal against phosphorylated BRCA1 amino acids 1489-1500 (Upstate Cell Signaling Solutions), and phosphorylated tau ...
From One-Bead One-Compound Concept to One-Bead One-Reactor.
Antopolsky Maxim, In PLoS ONE, 2006
... Protected amino acids and other residues for SPPS were purchased from Iris Biotech GmbH, Anaspec Inc., Aldrich, Luxembourg Industries ...
Gene amplification and overexpression of protein phosphatase 1α in oral squamous cell carcinoma cell lines
Hsu Lih-Ching et al., In International Journal of Biological Sciences, 2005
... BRCA1 cDNA sequence (containing the stop codon) was subcloned into pGFP-C3 (Clontech, Mountain View, CA, USA) ...
Identification of two evolutionarily conserved and functional regulatory elements in intron 2 of the human BRCA1 gene
Fu Sidney W. et al., In International Journal of Biological Sciences, 2004
... rabbit polyclonal antibody (Novus Biologicals) at a dilution of 1:5,000 in TNE buffer with 0.05% Tween, BRCA1 monoclonal antibody (Cat# NB100-598) (Novus Biologicals), which recognizes the epitope ...
The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function
Eritja Ramon et al., In Journal of Nucleic Acids, 2004
... Boc-(2-aminoethyl)glycine(Fmoc) (Boc-Aeg(Fmoc)-OH) was obtained from Iris Biotech and Fmoc-glycine (Fmoc-Gly-OH) was obtained from Bachem.
more suppliers
Papers on Iris
Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.
Mazoyer et al., Lyon, France. In Eur J Hum Genet, Feb 2016
We screened two genes, MIR146A and MIR146B, producing miR-146a and miR-146b-5p, respectively, that regulate BRCA1, and the 3'- untranslated regions (3'-UTRs) of BRCA1 and BRCA2 in the GENESIS French national case/control study (BRCA1- and BRCA2-negative breast cancer cases with at least one sister with breast cancer and matched controls).
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Campbell et al., Newcastle, Australia. In J Clin Oncol, Feb 2016
PATIENTS AND METHODS: Cases (n = 2,000) were predominantly breast cancer-affected women referred to specialized Familial Cancer Centers on the basis of a strong family history of breast cancer and BRCA1 and BRCA2 wild type.
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
Chen et al., Houston, United States. In Ann Oncol, Feb 2016
RESULTS: Of the 1000 patients who underwent sequencing, 43 had likely pathogenic germline variants: APC (1), BRCA1 (11), BRCA2 (10), TP53 (10), MSH2 (1), MSH6 (4), PALB2 (2), PTEN (2), TSC2 (1), and RB1 (1).
A two-stage approach to genetic risk assessment in primary care.
Parmigiani et al., Richardson, United States. In Breast Cancer Res Treat, Feb 2016
UNASSIGNED: Genetic risk prediction models such as BRCAPRO are used routinely in genetic counseling for identification of potential BRCA1 and BRCA2 mutation carriers.
Ovarian cancer treatment in mutation carriers/brcaness.
Perotto et al., Milano, Italy. In Minerva Ginecol, Feb 2016
Retrospective studies have shown an improved prognosis, higher response rates to platinum-containing regimens, and longer treatment-free intervals between relapses in patients with BRCA 1 and BRCA 2 (BRCA1/2)-mutated ovarian cancer (BMOC) compared with patients who are not carriers of this mutation.
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Hung et al., Houston, United States. In Nat Med, Feb 2016
BRCA1 and BRCA2 have essential roles in repairing DNA double-strand breaks, and a deficiency of BRCA proteins sensitizes cancer cells to PARP inhibition.
BRCAness revisited.
Ashworth et al., San Francisco, United States. In Nat Rev Cancer, Feb 2016
UNASSIGNED: Over the past 20 years, there has been considerable progress in our understanding of the biological functions of the BRCA1 and BRCA2 cancer susceptibility genes.
Artificial neural network-based exploration of gene-nutrient interactions in folate and xenobiotic metabolic pathways that modulate susceptibility to breast cancer.
Kutala et al., Thanjāvūr, India. In Gene, Feb 2016
Dietary intake of folate appears to confer protection against breast cancer through its modulating effects on ER and PR expression and methylation of EC-SOD and BRCA1.
CDH1 germline mutations and hereditary lobular breast cancer.
Galimberti et al., Milano, Italy. In Fam Cancer, Feb 2016
UNASSIGNED: Hereditary diffuse gastric cancer is an autosomal dominant inherited disease associated of CDH1 germline mutations (that encodes for the E-cadherin protein), and lobular breast cancer is the second most frequent type of neoplasia.
ER functions of oncogenes and tumor suppressors: Modulators of intracellular Ca(2+) signaling.
Bultynck et al., Leuven, Belgium. In Biochim Biophys Acta, Feb 2016
An important aspect of this is the identification of several major oncogenes, including Bcl-2, Bcl-XL, Mcl-1, PKB/Akt, and Ras, and tumor suppressors, such as p53, PTEN, PML, BRCA1, and Beclin 1, as direct and critical regulators of Ca(2+)-transport systems located at the ER membranes, including IP3 receptors and SERCA Ca(2+) pumps.
The cancer genetics and pathology of male breast cancer.
Fox et al., Melbourne, Australia. In Histopathology, Jan 2016
Furthermore, the genophenotypical association of basal-like cancer with BRCA1 present in female breast cancer is not observed in male breast cancer.
Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
Schmidt et al., Utrecht, Netherlands. In J Clin Oncol, Jan 2016
PURPOSE: To determine prospectively overall and age-specific estimates of contralateral breast cancer (CBC) risk for young patients with breast cancer with or without BRCA1/2 mutations.
A mechanism for the suppression of homologous recombination in G1 cells.
Durocher et al., Toronto, Canada. In Nature, Jan 2016
Here we report that the cell cycle controls the interaction of BRCA1 with PALB2-BRCA2 to constrain BRCA2 function to the S/G2 phases in human cells.
Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.
Skorski et al., Gainesville, United States. In Plos One, Dec 2015
It has been reported that inhibition of RAD52 either by specific shRNA or a small peptide aptamer induced synthetic lethality in tumor cell lines carrying BRCA1 and BRCA2 inactivating mutations.
The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
van Beekhuizen et al., Rotterdam, Netherlands. In Bmc Cancer, Dec 2015
BACKGROUND: To assess the clinical value of peritoneal washing cytology (PWC) in women with BRCA1 or BRCA2 mutations and women from a family with hereditary breast and/or ovarian cancer (HBOC) undergoing risk-reducing salpingo-oophorectomy (RRSO) in detecting primary peritoneal cancer (PPC) or occult ovarian/fallopian tube cancer.
BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
Jensen et al., Kansas City, United States. In Proc Natl Acad Sci U S A, 2012
BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activati
Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
Longacre et al., Stanford, United States. In Am J Surg Pathol, 2012
identified 5 morphologic features associated with BRCA1 mutation status in a series of 20 ovarian cancers
A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.
Jasin et al., New York City, United States. In Cancer Cell, 2012
show a repair-independent requirement for FA genes, including FANCD2, and BRCA1 in protecting stalled replication forks from degradation
[Prevalence of mutations BRCA1 5382insC, and CHEK2 1100delC in the population of Siberian region].
Liakhovich et al., In Genetika, 2012
Higher frequencies of these mutations in the patient group compared to the control sample (1.95 versus 0.25% for BRCA1 5382insC, and 1.78 versus 0.40% for CHEK2 1100delC) were observed, pointing to their association with susceptibility to breast cancer
Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with breast cancer and their relatives by PCR-SSCP method.
Hafez et al., Sūhāj, Egypt. In Egypt J Immunol, 2010
Sixty-two patients (index cases) with invasive breast cancer belonging to sixty families and their asymptomatic female first-degree relatives (300 cases) were studied for germline mutations of BRCA1 and BRCA2 genes.
More papers using Iris antibodies
Analysis of microarray data using Z score transformation
Haaf Thomas et al., In Epigenetics, 2002
... BRCA1 promoter was designed using the PyroMark Assay Design 2.0 software (Qiagen).
share on facebooktweetadd +1mail to friends